Crossmark

Safety and preliminary efficacy of sequential multiple ascending doses of solnatide to treat pulmonary permeability edema in patients with moderate to severe ARDS in a randomized, placebo-controlled, double-blind trial: preliminary evaluation of safety and feasibility in light of the COVID-19 pandemic

Crossref DOI link: https://doi.org/10.1186/s13063-022-06182-3

Published Online: 2022-04-04

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schmid, Benedikt

Kranke, Peter https://orcid.org/0000-0001-5324-981X
Lucas, Rudolf

Meybohm, Patrick

Zwissler, Bernhard

Frank, Sandra
Funding

Funding for this research was provided by:

Horizon 2020 (101003595)

Österreichische Forschungsförderungsgesellschaft (880862)
License Information

Text and Data Mining valid from 2022-04-04

Version of Record valid from 2022-04-04
More Information

Article History

Received: 24 February 2022

Accepted: 12 March 2022

First Online: 4 April 2022

Declarations

:

: This study was approved by the ethics committee of the Medical University Vienna, Austria (#2017/2017), and subsequently by the local ethics committees of all study sites.

: Not applicable

: The participating study centers receive a per-patient enrollment fee compensating for the expenses to conduct the study. RL is inventor on patents related to the protective role of Solnatide in pulmonary edema. The remaining authors declare no competing interests.

Document is current

Any future updates will be listed below